Anna Karolina Kocjan

• I am promoting medicines from the drug programmes: Cemiplimab (Libtayo) and Tebentafusp (Kimmtrak)
• I work with the following drug programmes: B.6 (non-small cell lung cancer), B125 (squamous cell carcinoma of the skin), B88 (basal cell carcinoma of the skin) and B159 (cervical cancer) and B163 fm (choroidal sarcoma) in the context of educating doctors on patient inclusion criteria, dosing regimens and diagnostic tests carried out as part of the programme
• Contributed to the roll-out of Cemiplimab and Tebentafusp in hospitals as part of the B6 and B163fm medicines programme, collaborating with ward managers, the procurement department, the medicines programme department, and hospital pharmacies.
• I was a co-organiser and initiator of a meeting of experts from southern Poland, who discussed and exchanged views on selecting the optimal treatment for patients with non-small cell lung cancer. It was the first meeting of its kind at Medison to be coordinated by the commercial department.
• I organise scientific meetings for doctors on wards, aimed at promoting Medison’s medicines through presentations and discussions, in which I highlight the benefits of treatment, the results of clinical trials and the effects of therapy, and provide information on side effects.
• I work closely with the marketing department, the medical department and the team to develop appropriate joint actions and strategies
• I manage the operational activities and budget within my area of responsibility independently, in accordance with the company’s guidelines aimed at achieving the set objective
• I have continually kept my knowledge up to date regarding products, clinical practices and trends in patient care
• I develop and maintain relationships with leading local specialists in oncology
• I achieve my set targets, and my line manager rates me as an ‘above-average’ employee in my half-yearly and annual performance appraisals
• I received an award in the ‘Impact Awards’ category

• I promoted the following medicines: Iclusig (ponatinib), Akynzeo (netupitant and palonosetron), Xydalba (dalbavancin)
• I worked on the B.14 drug programme (for the treatment of chronic myeloid leukaemia) and the B.65 programme (for the treatment of acute lymphoblastic leukaemia), providing training to doctors on patient inclusion criteria, dosing regimens and diagnostic tests carried out as part of the programme
• I was the initiator of the ‘Preceptorship’ educational project, the aim of which
  was to identify patients with CML more quickly and accurately according to
  the European LeukaemiaNet criteria
• I was the driving force behind the publication of a research paper, with KOL as a co-author, aimed at demonstrating the efficacy of treatment with ponatinib and the management of adverse effects in CML patients receiving treatment throughout Poland
• Through scientific interactions on hospital wards, I promoted the benefits of Angelini’s products based on the risk-benefit profile of our medicines, thereby helping to foster an innovative approach to the treatment of patients with CML and to support preventive measures in cancer care
• I managed the strategy, planning and implementation of activities within my area of responsibility, whilst ensuring the effective use of the budget
• I supported the marketing department in updating and creating promotional materials, and the medical department in initiating research projects
• I have been selected to take part, alongside my KOLs, in the European Haematology Association (EHA) conference

• In May 2019, I was promoted to the position of Hospital Market Specialist.
• In the inpatient care sector, I was responsible for managing tenders
  for the following products: Enfamil, Nutramigen, Phenyl-Free
• I achieved the best sales results in Poland
• I analysed sales data for my assigned territory
• I drew up budget proposals for my brand
• I took part in meetings that had a key impact on the

business unit of the company entrusted to me

• I was appointed to stand in for the regional manager during his absence
• In addition, my responsibilities included working with the Metabolic Disorders Clinic on matters relating to phenylketonuria.
• I worked with pharmacies and the logistics department to ensure product availability
• I organised educational sessions with patients

Representative of the Year 2020

• I promoted products from the company’s portfolio to doctors (paediatricians, allergists,
  gastroenterologists) and midwives
• I delivered training sessions and presentations to healthcare staff
• I took part in focus group meetings as a representative of
  the region
• I monitored the activities of our competitors
• I trained new staff to work at the company

‘On The Spot Award’ – for achieving sales growth in
2017

• I played an active role in setting up the company
• I managed a property agency
• I acted as an agent in the sale/purchase and letting/rental of properties
• I acquired new clients by establishing, maintaining and
  developing business relationships
• I worked with the legal profession on commercial
  transactions

• Developed and implemented advertising strategies for current property developments.
• I prepared the documents required to complete transactions
• I monitored the timely fulfilment of obligations
• Acquired insights into property brokerage to enhance professional expertise.